Decline in opioid deaths masks new danger from designer drug overdoses
Talks about opioid epidemic, drug overdose deaths and fentanyl
SG
Scott Gottlieb
Partner, New Enterprise Associates
Washington, District of Columbia
Overview
Scott Gottlieb is a Partner at New Enterprise Associates, with a notable background in health policy and strategic planning. He has served on the board of various prominent organizations and has made significant investments in healthcare companies, including Xaira Therapeutics and Comanche Biopharma.
Gottlieb's career highlights include being a Senior Fellow at the American Enterprise Institute and serving on the board of directors for Pfizer.
Work Experience
Partner
2007 - Current
NEA is one of the world’s largest and most active venture capital firms with headquarters in Chevy Chase and Palo Alto. With over $18 billion in assets under management, NEA ranks as the world's largest venture capital firm. Since its founding, NEA invested in over 650 companies, and realized nearly 500 liquidity events (with close to 200 portfolio company IPOs and 300 acquisitions), making NEA one of the most prolific and successful venture capital firms. The firm has deep domain expertise into growth industries that include, among other areas; life sciences, medical technology, healthcare services, clean energy, consumer technology, media, enterprise solutions, and telecom.
New Enterprise Associates is a venture capital firm that focuses on investments in technology and healthcare startups.
Senior Fellow
2003
Tech Policy Daily offers research and commentary on broadband, FCC policy, cybersecurity, and competition in high-tech industries.
Elected Member
2018
National Academy of Medicine is a medical organization that offers advisory services to the national and international community.
Member of the Board of Directors
2019
Pfizer is a biopharmaceutical company that provides affordable access to safe, effective medicines and health care services.
Raised $32,000,000,000.00 from Starboard Value.
Board Member
2020
Illumina is an innovative technology and revolutionary assays aiming the analyze genetic variation and function.
Raised $1,278,000,000.00 from Bank of America.
Board Member
2024
Xaira Therapeutics is an integrated biotechnology company driving advances in artificial intelligence.
Raised $1,000,000,000.00 from Lux Capital, SV Angel, Two Sigma Ventures, F-Prime Capital, R-Squared Ventures, Foresite Capital, Byers Capital, ARCH Venture Partners, Lightspeed Venture Partners and New Enterprise Associates.
Board Member
2024
Our purpose is to make every pregnancy around the world safer.
Raised $111,100,007.00 from Atlas Venture, F-Prime Capital, Lilly Asia Ventures, Google Ventures, New Enterprise Associates and Longview Ventures.
Board Member
2020
Resilience is a biomanufacturing company that provides access to complex medicines and protects biopharmaceutical supply chains.
Raised $2,532,500,000.00 from Administration for Strategic Preparedness and Response.
Board Member
2019
Board Member
2019
Aetion provides real-world evidence (RWE) and outcomes-based analytics solutions to life science companies and payers.
Raised $203,600,000.00 from B Capital, Warburg Pincus, Foresite Capital, Flare Capital Partners and New Enterprise Associates.
Education
Investments
Latest Articles
Op-ed: We need to prepare for US outbreak of Wuhan coronavirus
Talks about Wuhan coronavirus outbreak, global spread of coronavirus and diagnostic testing for coronavirus
Op-ed: Gottlieb says A.I. may take on doctors' roles sooner rather than later
Talks about AI in healthcare, machine learning and natural language processing
Generative AI in Healthcare: Transforming Medicine | NEA
Talks about Generative AI in healthcare, Healthcare technology transformation and Clinician burnout